Renal Cell Carcinoma: Molecular Targets And Clinical Applications Renal Cell Carcinoma (bukowski)

The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, __Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition__ is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​ Front Matter....Pages i-xviii Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction....Pages 1-14 Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets....Pages 15-38 Genomic Assessment of Renal Cancer....Pages 39-56 VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications....Pages 57-110 PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex....Pages 111-151 Sporadic RCC: Abnormalities in Histone-Modifying Genes....Pages 153-165 Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?....Pages 167-176 First-Generation Tyrosine Kinase Inhibitors: Clinical Results....Pages 177-205 Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status....Pages 207-216 Third-Generation TKIs (Axitinib, Tivozanib) in RCC: Enhanced Efficacy and Diminished Toxicity?....Pages 217-236 Anti-VEGF and VEGFR Monoclonal Antibodies in RCC....Pages 237-252 PI3-kinase, Akt, and mTOR Inhibitors in RCC....Pages 253-262 Carbonic Anhydrase IX and Monoclonal Antibody G250: Relevance as a Clinical and Biologic Target in Renal Cell Carcinoma....Pages 263-284 EGFR and HER2: Relevance in Renal Cell Carcinoma....Pages 285-302 The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma....Pages 303-318 Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance....Pages 319-348 Development of Combination Therapy with Targeted Agents....Pages 349-375 Side Effects of Targeted Therapy....Pages 377-416 The Role of Targeted Therapy in Special Populations....Pages 417-439 Immunotherapy: The Current Role of Cytokines....Pages 441-467 Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC....Pages 469-481 Vaccines in RCC: Clinical and Biological Relevance....Pages 483-525 Development and Incorporation of Biomarkers in RCC Therapeutics....Pages 527-539 Molecularly Targeted Staging Strategies in Renal Cell Carcinoma....Pages 541-553 Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma....Pages 555-567 The Role of Advocacy in Renal Cell Carcinoma....Pages 569-599 Back Matter....Pages 601-613 ​​ ​The third edition of this critically acclaimed book has updated and expanded the survey of clinical, biological and pathological management of localized and advanced renal cell carcinoma. Internationally renowned editors and contributors explore the latest developments in molecular genetics, focusing on the novel targets that have been discovered in epithelial renal tumors. Comprehensive and authoritative, Renal Cell Carcinoma: Molecular Targets and Clinical Applications, Third Edition is the definitive text on the rapidly evolving landscape of experimental therapeutics, written and edited by leaders of the field.​ References; Chapter 2: Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets; Evolution of the Classification of Renal Cell Carcinomas; Initial Histological Classifications; Chromosomal Findings in Familial Renal Cell Carcinomas: Impact on the Pathology and Therapy of Sporadic Cases; Molecular Pathways in Renal Cell Carcinomas; Pseudo-hypoxic Pathways in Renal Cell Carcinoma; VHL Pathway; Krebs Cycle and Pseudo-hypoxic Pathway; mTOR Pathway; TSC1/TSC2 Pathway; c-MET Pathway in Renal Cell Carcinoma; FLCN Pathway in Renal Cell Carcinoma Ronald M. Bukowski, Robert A. Figlin, Robert J. Motzer, Editors. Includes Bibliographical References And Index. Mode Of Access: World Wide Web.